SAN DIEGO, CA, July 14, 2025 - MPNT Research Institute announces the public release of its breakthrough biotechnology platform: Modular Peptide Nano Technology
Existing treatment options are limited, often toxic, and poorly bioavailable. AMOEBASHIELD™ addresses these limitations with the following innovations:
Nano-LL-37 Analog Peptides
Mimic natural antimicrobial cathelicidins, disrupt trophozoite membranes, and potentially weaken the cyst wall architecture.
Nano-Andrographolide and Berberine
Exhibit broad-spectrum protozoal activity, reduce inflammatory damage, and synergize with AMPs for pathogen clearance.
Immunopeptides + L-Arginine/Glutamine
Stimulate NO-mediated immune killing, restore gut-immune axis function, and support lymphocyte proliferation in immune-deficient hosts.
Nano-Curcumin and Echinacea/Astragalus Fractions
Provide systemic and local immune modulation, including macrophage activation and antioxidant buffering of inflamed or necrotic lesions.
Why MODULAR PEPTIDE NANO TECHNOLOGY™ is Superior to Other Natural Formulations
Unlike conventional herbal capsules or tinctures—which often rely on unprocessed extracts with limited bioavailability—Modular Peptide Nano Technology™.-based supplements are engineered therapeutic systems. They offer:
- Defined bioactive peptides with pharmaceutical-like targeting ability CNS and dermal penetration for deep infection sites (especially for AGE and cutaneous lesions)
- Synergistic interaction between natural and bioengineered molecules Standardized nanocarriers for reproducible dosing, encapsulation, and controlled release
Potential for FDA botanical-drug or dietary supplement dual-pathway approval This system represents the next generation of natural therapeutics: biologically intelligent, clinically relevant, and scalable for production.
Conclusion: A New Era in Anti-Amoebic Natural Medicine
The AMOEBASHIELD™ Herbal-Amino supplement is a scientifically engineered, patent-pending innovation designed to fill a critical gap in managing cutaneous and systemic Acanthamoeba infections in both immunocompetent and immunocompromised individuals.
The underlying Modular Peptide Nano Technology™ platform allows us to move far beyond what current supplement or phytomedicine companies' offer—creating bioavailable, multi-modal, and intelligent nano-therapies rooted in natural biomolecular engineering.
This technology and formulation are fully owned and developed by the MPNT Research Institute, and are protected under Patent pending# 63/838,981 intellectual property claims for Modular Peptide Nano Technology™.
Contact Information
Willy Ramos
MPNT Research Institute
Oceanside, California
United States
Telephone: 7607170957
